This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dawson, L. A. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Dawson, L. A. Articles by Lawrence, T. S. Social Bookmarking                            What's this?

Escalated Focal Liver Radiation and Concurrent Hepatic Artery Fluorodeoxyuridine for Unresectable Intrahepatic Malignancies

From the Departments of Radiation Oncology, Internal Medicine, and Pharmacology, University of Michigan, Ann Arbor, MI.

Address reprint requests to Laura A. Dawson, MD, Department of Radiation Oncology, University of Michigan, UH-B2C447, 1500 E Medical Center Dr, Ann Arbor, MI 48109-0010; email dawson@ umich.edu.

PURPOSE: To evaluate the response, time to progression, survival, and impact of radiation (RT) dose on survival in patients with intrahepatic malignancies treated on a phase I trial of escalated focal liver RT.

PATIENTS AND METHODS: From April 1996 to January 1998, 43 patients with unresectable intrahepatic hepatobiliary cancer (HB; 27 patients) and colorectal liver metastases (LM; 16 patients) were treated with high-dose conformal RT. The median tumor size was 10 x 10 x 8 cm. The median RT dose was 58.5 Gy (range, 28.5 to 90 Gy), 1.5 Gy twice daily, with concurrent continuous-infusion hepatic arterial fluorodeoxyuridine (0.2 mg/kg/d) during the first 4 weeks of RT.

RESULTS: The response rate in 25 assessable patients was 68% (16 partial and one complete response). With a median potential follow-up period of 26.5 months, the median times to progression for all tumors, LM, and HB were 6, 8, and 3 months, respectively. The median survival times of all patients, patients with LM, and patients with HB were 16, 18, and 11 months, respectively. On multivariate analyses, escalated RT dose was independently associated with improved progression-free and overall survival. The median survival of patients treated with 70 Gy or more has not yet been reached (16.4+ months), compared with 11.6 months in patients treated with lower RT doses (P = .0003).

CONCLUSION: The excellent response rate, prolonged intrahepatic control, and improved survival in patients treated with RT doses of 70 Gy or more motivate continuation of dose-escalation studies for patients with intrahepatic malignancies.

Presented in part at the Thirty-Fifth Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Krishnan, L. A. Dawson, J. Seong, Y. Akine, S. Beddar, T. M. Briere, C. H. Crane, and F. Mornex Radiotherapy for Hepatocellular Carcinoma: An Overview Ann. Surg. Oncol., April 1, 2008; 15(4): 1015 - 1024. [Full Text] [PDF]

				R. V. Tse, M. Hawkins, G. Lockwood, J. J. Kim, B. Cummings, J. Knox, M. Sherman, and L. A. Dawson Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma J. Clin. Oncol., February 1, 2008; 26(4): 657 - 664. [Abstract] [Full Text] [PDF]

				L. A. Dawson Radiation Therapy for Liver Metastases ASCO Educational Book, January 1, 2008; 2008(1): 161 - 164. [Abstract] [Full Text] [PDF]

				C. H. Chou, P.-J. Chen, P.-H. Lee, A.-L. Cheng, H.-C. Hsu, and J. C.-H. Cheng Radiation-Induced Hepatitis B Virus Reactivation in Liver Mediated by the Bystander Effect from Irradiated Endothelial Cells Clin. Cancer Res., February 1, 2007; 13(3): 851 - 857. [Abstract] [Full Text] [PDF]

				E. Ben-Josef, D. Normolle, W. D. Ensminger, S. Walker, D. Tatro, R. K. Ten Haken, J. Knol, L. A. Dawson, C. Pan, and T. S. Lawrence Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies J. Clin. Oncol., December 1, 2005; 23(34): 8739 - 8747. [Abstract] [Full Text] [PDF]

				M.-T. Liu, S.-H. Li, T.-C. Chu, C.-Y. Hsieh, A.-Y. Wang, T.-H. Chang, C.-P. Pi, C.-C. Huang, and J.-P. Lin Three-dimensional Conformal Radiation Therapy for Unresectable Hepatocellular Carcinoma Patients who had Failed with or were Unsuited for Transcatheter Arterial Chemoembolization Jpn. J. Clin. Oncol., September 1, 2004; 34(9): 532 - 539. [Abstract] [Full Text] [PDF]